https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Genetic risk score mendelian randomization shows that obesity measured as body mass index, but not waist:hip ratio, is causal for endometrial cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30306 Wed 15 Dec 2021 16:09:28 AEDT ]]> Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47747 Tue 21 Mar 2023 19:00:49 AEDT ]]> Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): A double-blind, randomised controlled trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24206 Thu 04 Nov 2021 10:38:26 AEDT ]]> Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:17176 Sat 24 Mar 2018 08:06:32 AEDT ]]> Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: Patient-reported outcomes in the suppression of ovarian function trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:23220 Sat 24 Mar 2018 07:10:38 AEDT ]]> Treatment adherence and its impact on disease-free survival in the breast international group 1-98 trial of tamoxifen and letrozole, alone and in sequence https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30333 Fri 01 Apr 2022 09:24:55 AEDT ]]>